Locally Advanced Pancreatic Cancer

  • Georgios Michael Oikonomopoulos Second Oncology Clinic, St. Savvas Anticancer Hospital. Athens, Greece
  • Kathryn E Huber Tufts Medical Center. Boston, MA, USA
  • Konstantinos N Syrigos Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital. Athens, Greece
  • Muhammad Wasif Saif Tufts Medical Center. Boston, MA, USA
Keywords: Chemoradiotherapy, Adjuvant, Drug Therapy, Neoadjuvant Therapy, Pancreatic Neoplasms


Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied. The authors summarize three abstracts (#LBA146, #256 and #303) presented on the 2013 ASCO Gastrointestinal Cancers Symposium, which were focused on treatment of locally advanced pancreatic cancer. A discussion is presented about the different chemotherapy or chemoradiotherapy regimens, that move away from gemcitabine-based treatment, and the effort to find less toxic, but efficient therapeutic combinations.

Image: St. Savvas Anticancer Hospital. Athens, Greece.


Download data is not yet available.


Conroy T, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. NEJM 2011;364:1817-1825

Moore MJ, Et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

G. R. Oliver, et al. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic [abstract] Gastrointestinal Cancers Symposium 2010:180

Lowery MA, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16(10):1397-402. doi: 10.1634/the oncologist.2011-0185. Epub 2011 Sep 20.

Cunningham D, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin Oncol 2009;27:5513-5518

Boeck S, et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs. 2010 Jan;21(1):94-100. doi: 10.1097/CAD.0b013e32833123ed.

Pelzer U, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group Eur J Cancer. 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011. Epub 2011 May 10.

Kim R, et al. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP. 2007 May 9;8(3):279-88.

Loehrer PJ Sr, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011 Nov 1;29(31):4105-12. doi: 10.1200/JCO.2011.34.8904. Epub 2011 Oct 3.

Huang J, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol. 2011 May;99(2):114-9. doi: 10.1016/j.radonc.2011.05.038. Epub 2011 May 27.

Somnath Mukherjee, et.al SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC) J Clin Oncol 30:2012 (suppl 34;abstr LBA 146)

Brian A. Boone et al. Outcomes with FOLFIRINOX for locally advanced pancreatic cancer. J Clin oncol 30:2012 (suppl 34;abstr 256)

Bradley Thomas Sumrall et al. A single-center experience of modified FOLFOX-6 in locally advanced and metastatic pancreatic adenocarcinomas J Clin oncol 30:2012 (suppl 34;abstr 303)

St. Savvas Anticancer Hospital. Athens, Greece
How to Cite
OikonomopoulosG., HuberK., SyrigosK., & SaifM. (2013). Locally Advanced Pancreatic Cancer. JOP. Journal of the Pancreas, 14(2), 126-128. https://doi.org/10.6092/1590-8577/1469
Highlights from the “2013 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 24-26, 2013

Most read articles by the same author(s)

1 2 > >>